Compare Nebius Group NV (NBIS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Tempus AI — how do they compare? Nebius Group NV trades at $221.12 (market cap $59.73B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Nebius Group NV is far larger — about 4.7× Tempus AI's market cap, and Nebius Group NV is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Tempus AI for 23 Days on average.
| NBIS | TEM | |
|---|---|---|
Market Cap | $59.73B | $12.58B |
Volume | 21,563,700 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $286.69 | $99.28 |
52-Week Low | $73.87 | $41.55 |
Typical Hold Time | 24 Days | 23 Days |
Enterprise Value | $61.86B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $219.71, down 7.32% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth projections ($530M in 2025 to $1.4B in 2026) but thin net margins (3.13%) and elevated valuations (P/E 845). Recent earnings beat expectations in Q1 and Q2 2026, while analyst sentiment remains overwhelmingly bullish with 82% buy ratings and a $288.67 consensus target.
The outlook balances high-growth AI infrastructure demand against execution risks and rich valuations. Near-term support lies at $214, with upside potential to $288 if operational scaling continues. Key risks include competitive pressure, heavy capital expenditure, and insider selling activity noted in recent filings.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
